Connecting to LinkedIn...

Icahn has snapped up a Bristol-Myers stake. Could megamerger pressure be far behind?

Posted on 8 months ago by Gerry Kennedy

Blank

 

Wednesday, February 22, 2017

Activist investor Carl Icahn has moved into Bristol-Myers Squibb, touching off more megamerger speculation. After all, the company has seen a major reversal of fortunes since its immunotherapy Opdivo fell short in a key lung cancer study last fall, and just yesterday, it bowed to another activist by adding three directors to its board.

Write something here...